In Brief: Elan selegilene
Executive Summary
Elan selegilene: Company acquires rights to fast-dissolving selegilene formulation using R.P. Scherer's Zydis technology in North America, U.K. and Ireland. Selegilene Zydis will be marketed in the U.S. by Elan subsidiary Athena Neurosciences. The product is in Phase III in the U.S. for Parkinson's disease...